Podfest Multimedia Expo’s 2024 Masterclass will provide education on A.I. & Creator Tools over April 19th, 22nd, 23rd, and 24th. Taking place online, the four-day event brings the latest technological revolution directly to attendees’ screens with case studies, How To’s, and breakout sessions with cutting edge topics. The virtual summit will benefit audio and video creators at all levels, whether beginner, intermediate, or advanced. The AI & Creator Tools program has been designed to help its attendees stay ahead of the game in content creation.

Over the four days of the event, education will include sessions such as, “Teach ChatGPT to Respond Like You,” “AI/Automation Workflows for Video Podcasters,” “How to Use AI to Create Content You Own Without Being Sued,” and “5 ChatGPT Prompts to Turn Your Podcast Transcript Into Engaging Marketing Messages,” to name just a few. The full session schedule has just been released and is packed with not only education but even opportunities for networking and virtual visits with exhibitors!

With AI and related creator tools evolving almost daily, it has become crucial for members of the podcast community to continually learn in order to stay on top of the podcast process. Dramatic efficiencies are now available with the latest AI tools, providing an easier workflow, and thus allowing room for more creativity, on the way to making episodes more meaningful to listeners, setting them up to keep coming back for more.

Podfest Multimedia Expo brings together a community of people anxious to share valuable ideas and content with an expanding world, serving experienced or aspiring podcasters supporting one another through information exchange and education, and invaluable networking. Podfest Expo is an important member of your podcast team.

Registration information is as follows:

Categories Of Passes:

• Creator Pass: $49.00+$5.13 Fee

This entry ticket access includes: Every session LIVE during the event on April 19, 22-24

Does not include: Premium Sessions – Lifetime Access to Podfest Masterclass Recordings

• VIP (Creator + Lifetime Recordings): $149.00+$11.83 Fee

This entry ticket access includes: Access to All Tracks at Podfest Masterclass and lifetime recordings of every track Everything with Creator Pass – All recordings of the entire event with every session

Does not include: Access to Premium Sessions

• Premium (VIP + High Level Education): $249.00+$18.54 Fee

This entry ticket access includes: Everything included with the VIP Pass Recordings of the Premium Sessions AMA (ask me anything) and Exclusive Networking with Industry experts Includes a Pay-it-Forward Creator Level pass for someone less fortunate

• Speaker Pass (Only for confirmed speakers): $99.00+$8.48 Fee

This entry ticket access includes: Everything with Creator Pass Access to the LIVE Premium Sessions Your own recorded session Branded graphics.

Does not include: Lifetime Recordings of the whole event.

The Podfest Masterclass 2024 is being held as a virtual event, and brings powerful speakers to the Podfest forum to engage, teach, and spread awareness among enthusiasts globally. The speakers are influential people from their respective fields and include dignitaries, influencers, and thought leaders.

To learn more, visit https://podfestexpo.com/masterclass/.

• Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients
• AVERSA technology can be incorporated into any transdermal patch
• The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia
• Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch
• In April 2024, the company announced it had received a contract manufacturing order from Fit For Life Group, with a supplier agreement to follow

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (“ADHD”). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Developed under Lavish Entertainment, a wholly owned subsidiary of GTVH, Destino Ranch will be a one-of-a-kind destination that revolutionizes the concept of an immersive music and art venue.
• Phase one development begins after the execution of a land-use-and-development agreement outlining exclusive rights to purchase, use and operate the nearly 70-acre property. Additional upgrades on the initial property secured will “dramatically increase speed into the market.”
• Marco Moreno has been appointed as president of Lavish Entertainment to spearhead the development of Destino Ranch. Mr. Moreno has notable experience in the large-scale event development industry with high-fidelity collaborations through his company ABI Create.

Two months ago, Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, announced plans to develop a one-of-a-kind immersive entertainment venue (https://ibn.fm/1gHcL). In the past few weeks, GTVH and Lavish have made significant progress in transforming into reality the vision for the premier destination for year-round, world-class music, entertainment and art.

“The development of Destino Ranch ushers in a new and beyond-amazing chapter for Lavish Entertainment,” said Steffan Dalsgaard, CEO of GTV and founder of Lavish Entertainment. The companies “truly believe this flagship project will be a one-of-a-kind location and resort that revolutionizes what people think of as a music and art venue. Our plan is to develop a world-renowned destination that offers a superior level of amenities, services, exhibits and attractions, along with so much more than just a festival ground.”

Since the announcement of Destino Ranch, a planned 638-acre property conveniently located within a short drive from large population centers such as Phoenix, Los Angeles and Las Vegas, Lavish Entertainment has officially activated the first phase of development (https://ibn.fm/2h4IH). This phase includes the execution of a land-use-and-development agreement outlining exclusive rights to use and operate on the property.

Phase one development will focus on developing the first nearly 70-acres of land that already has in place substantial infrastructure features, such as special-event permits, graded roads, fencing, storage, septic, solar, landscaping, and water and irrigation rights. Further development in phase one will include site event plans and permitting, site prep and cleanout, staff infrastructure and housing, a temporary power grid, and event features and infrastructure.

In addition, last month Lavish Entertainment announced that it has executed a purchase agreement to acquire this first, nearly-70 acres of land that the company recently secured, which is prime and improved property for the Destino project (https://ibn.fm/WyV4R). The company noted that the upgrades were valued at nearly $6 million, which “has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.”

Lavish Entertainment president Marco Moreno stated: “With a strong background of delivering high-fidelity productions to notable large-scale installations such as EDC and the Super Bowl, Destino Ranch is the culmination of more than a decade of experience in the planning and execution of large-scale event projects and production. Our goal is to provide guests with memorable and life-changing experiences that captivate their minds for years to come. As we anticipate Destino Ranch becoming a globally renowned attraction, we are proud to showcase the launch of this project and look forward to sharing more exciting developments with our shareholders in the weeks ahead.”

For more information, visit www.GoldenTriangleInc.com and www.DestinoRanch.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• Bebuzee in November 2023 announced completion of its superapp, which combines multiple digital services into a single, user-friendly platform for the U.S. and European markets
• In September 2022, the company filed with the SEC for a Regulation A registration exempt public offering of up to $75 million of its common shares
• The company in April 2022 announced a private placement offering of up to $10 million of its common shares

Bebuzee (OTC: BBUZ), formerly Engage Mobility Inc., is a social platform and streaming service focused on development and deployment of America’s first superapp. The superapp will allow members to watch a wide variety of content, such as movies, series, documentaries and talk shows, on any internet-connected device.

Bebuzee’s technology scans the world’s news, features and information-flow to give its dedicated readers the best of the internet in one place – a one-stop platform for breaking news, interesting and important blogs, videos and photos.

The core features of the superapp include video streaming; photo sharing; Bebuzee Messaging service, which allows users to send text and voice messages and make voice and video calls; Shortbuz, used to make a variety of short-form entertaining videos; Blogbuz, a resource for people without time to scavenge the internet and other sources for news and information; Properbuz global real estate search; global tradesmen search; location reviews of neighborhoods, cities and even regions to help others find their ideal rental or real estate purchase; ShoppingBuz, a unique technology-driven e-commerce platform which gives merchants incredible tools to sell their products; Bebuzee Pay, a mobile payment and digital wallet service that allows users to make mobile payments and online transactions; TravelBuz, an online travel booking service; EventBuz, a ticket exchange and resale platform; and FlightBuz, a flight search engine.

The company is headquartered in Miami.

Introducing the Superapp to Western Markets

A superapp is a mobile phone app that offers a wide range of services within a single platform. This technology allows users to access various services without downloading and switching between multiple apps.

While superapps are popular in many parts of the world, including Latin America, Africa, the Middle East, Asia and Russia, they have achieved little adoption in Western markets. Perhaps the most widely known superapp is WeChat, which is estimated to have as many as 1.24 billion users, mostly in China.

Bebuzee aims to be the first developer to introduce and grow to widespread popularity a superapp in the U.S. and Europe. It took a strong step toward achieving this goal during the COVID-19 pandemic, when Bebuzee’s user base surged by 78% with over 42 million new users.

Whereas most social platforms are generic and only local postings make them somewhat relevant to local communities, Bebuzee has localized its platform for most countries by providing local content, entertainment and information that is frequently updated and refreshed.

The company says the average age of its superapp users is 39, with female users making up 62.8% of its user base. Its monetization strategy includes sales of video advertising, sponsored posts, banner ads and premium listings, as well as promotion of featured brands and property listings.

Market Opportunity

A report from Allied Market Research, a global market research, consulting and advisory firm, estimated that the worldwide superapps market was valued at $58.6 billion in 2022. The report projects the market to expand to $722.4 billion by 2032, growing at a CAGR of 28.9% for the forecast period.

The report identifies a few of the most popular superapps as Rappi in Latin America, Snapp in Iran, Line in Japan and Yandex Go in Russia and Kazakhstan.

Increasing adoption of mobile services and growing advancements in digital technologies are driving the growth of this market. In addition, a rise in government support for promoting the use of superapps is lending to expansion, according to the report.

Integration of blockchain technology in superapps is likewise anticipated to provide numerous opportunities for the expansion of the market during the forecast period, the report states.

Management Team

Joseph Onyero is Founder and CEO of Bebuzee. He has a background of managing multiple products from ideation to market launch and profitable monetization and has been building commercial web presences since 2005. He has worked as a Chief Marketing Officer and in business development. He previously owned and operated a travel and tourism company. He began in 2005 working on the concept and features that have evolved into the Bebuzee suite. He has grown Bebuzee from a living room start-up into a U.S. publicly traded company.

Claudia S. Spagnuolo is Chief Operating Officer at Bebuzee. She began with the company in 2014 as a user experience manager before being promoted to CMO in 2017. She previously worked as an assistant marketing director at the National Secretariat of the union CISL in Italy. Prior to that, she also worked as a researcher at the Complutense University of Madrid on issues of corporate management. She speaks three languages and holds a bachelor’s in political science and a master’s in administration from the University of Perugia in Italy.

For more information, visit the company’s website at www.Bebuzee.com.

NOTE TO INVESTORS: The latest news and updates relating to BBUZ are available in the company’s newsroom at https://ibn.fm/BBUZ

• SenesTech, a company that offers fertility control products for rodent pests, launched Evolve(TM) Soft Bait in October 2023, and has so far inked multiple distribution agreements as part of its multi-prong go-to-market strategy for the product
• The company recently announced it had signed a distribution agreement with Wilco Distributors Inc., a Glendale, Arizona-based distributor of pest management baits and tools to the rodent pest management market
• In addition to Evolve, SenesTech also offers ContraPest(R), a highly palatable professional-grade contraceptive liquid formulation for both male and female rats
• Evolve and ContraPest are positioned as effective non-lethal alternatives to registered rodenticides that can pose a danger to other animals

Committed to the sustainable, humane treatment of animals, SenesTech (NASDAQ: SNES) offers a one-of-a-kind technology for managing rat pest populations through safe fertility control. The company’s first product, ContraPest(R), is a highly palatable professional-grade contraceptive liquid formulation that targets the reproductive capabilities of both male and female rats to reduce their fertility. While ContraPest works, SenesTech observed that its liquid nature does not meet all customer/business preferences.

This led to the introduction in October 2023 of the non-liquid Evolve(TM) Soft Bait, which has similar efficacy to ContraPest but is in a solid form that is better accepted by the pest control industry, according to Joel Fruendt, SenesTech’s President and CEO (https://ibn.fm/pddhC). In addition, Evolve has a long shelf life, is easy to use, and is available at an excellent price point. Since October, SenesTech has implemented a multi-prong go-to-market strategy for Evolve, which has seen the company sell the new innovative product to customers through e-commerce platforms, its in-house direct sales team, and distributors.

SenesTech has so far inked multiple distribution agreements with many new and significant partners, helping the company get Evolve into the marketplace in the United States and abroad. Recently, the company signed a distribution agreement with Wilco Distributors Inc., a Glendale, Arizona-based family-owned distributor of pest management baits and tools to the rodent pest management market. Under the terms of the agreement, Wilco Distributors will be a stocking distributor for Evolve. Wilco Distributors has already placed its initial multi-pallet stocking order (https://ibn.fm/MLvtR).

“We are particularly pleased to be partnering with Wilco Distributors, as they have a clear commitment to finding innovative and responsible products for rodent pest management and a strong position in the agriculture space,” said Fruendt of the signed distribution agreement and SenesTech’s new partner.

Wilco Distributors’ President Blake Hazen commented on the partnership with SenesTech, saying, “Our mission is to manufacture and distribute quality rodent control products, both for homeowners and professionals, providing effective and efficient solutions and excellent customer service. SenesTech’s fertility control products fit extremely well into our portfolio, and we are excited to introduce our customers to Evolve and ContraPest. We already have products in stock and we are fulfilling initial orders.”

Numerous independent studies have shown that the active ingredients in ContraPest and Evolve, which are specifically formulated for rats and break down in their digestive systems, effectively reduce fertility in rodents. In this regard, ContraPest and Evolve can help control the rapid reproduction of rats, which, if left unchecked, can lead to overpopulation. A 2017 study puts this into perspective: a pair of rats can produce 500 million descendants in just three years (https://ibn.fm/zHOTN).

Given their unique capabilities and properties, ContraPest and Evolve are well positioned as more effective alternatives to registered rodenticides and poisons, which are linked to adverse effects. Rodenticides and poisons are known to move through the food chain when non-target animals prey on the poisoned rodents. This results in secondary and sometimes tertiary poisoning of other animals, leading to their deaths (https://ibn.fm/kffSe). Such adverse results have forced regulators to act, with states around the country sanctioning stricter regulations on commonly used poisons. For instance, last year, California Governor Gavin Newsom signed a bill that offered greater protections against rodenticides (https://ibn.fm/7lCbr). These developments have incentivized pest managers to look elsewhere.

“Pest management professionals and homeowners are seeking alternatives to traditional lethal methods and poisons, as poisons are highly regulated and are tricky to use without contamination, and traps are expensive and time-consuming to maintain,” conveyed Fruendt. “There is strong evidence that the addition of fertility control to an integrated pest management program increases efficacy and reduces the reliance on poison.”

SenesTech expects to capitalize on its product’s contraceptive capabilities to tap into the rodent pest control market, which represents a significant opportunity. Analysts at Straits Research project that the market will grow at a CAGR of 6.19% between 2023 and 2031, reaching an estimated $4.91 billion by 2031 from $2.86 billion in 2022 (https://ibn.fm/VHvEv).

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging
• CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function
• Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast

In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function. The potential of this drug to treat multiple neurological diseases was highlighted during the latest episode of the “First In Human” podcast, hosted by Vial’s Executive Vice President of CRO Operations, Rich McCormick, featuring Clene’s CEO, Rob Etherington (https://ibn.fm/7eCrw).

Etherington, who has nearly 32 years of experience in pharmaceutical drug development, discussed the journey of CNM-Au8 from its conception to the promising results of clinical trials. These trials have demonstrated the drug’s potential to significantly enhance neurological functions, offering new hope to individuals battling Amyotrophic Lateral Sclerosis (“ALS”) and Multiple Sclerosis (“MS”).

The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function, and more. Etherington highlighted that CNM-Au8 is tailored to address the central nervous system’s needs, targeting diseases like ALS and MS.

“For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain,” Etherington said. “We had the idea to do that with a catalytically active nanotherapeutic suspension, which the patients drink daily.”

Clinical trials of CNM-Au8 have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging. This breakthrough has the potential to significantly improve survival and quality of life for patients with neurodegenerative diseases, offering improvements in movement, speech, and overall function.

One of the key differences of CNM-Au8 is its oral consumption method, providing an easily accessible treatment option for patients. Its strong safety profile, without a single reported serious adverse event related to the drug, positions CNM-Au8 as a revolutionary treatment that can be administered alongside standard of care.

Clene’s commitment to addressing neurodegenerative diseases aligns with the urgent need for therapeutic breakthroughs in this field. The World Health Organization has predicted that neurodegenerative disease will become the second most prevalent cause of death within the next 20 years, making innovations like CNM-Au8 critical.

The development of CNM-Au8 has not been without challenges, including the complexity of creating a nanotherapeutic with medicinal efficacy and navigating regulatory pathways. Despite these hurdles, Clene has emerged as a leader in the field, with CNM-Au8 showing promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function.

Etherington also highlighted Clene’s collaborative efforts, including partnerships with academic centers of excellence and a significant grant from the National Institutes of Health. These collaborations have been instrumental in advancing the development of CNM-Au8 and understanding its mechanisms.

Looking ahead, Clene Inc. aims to transform healthcare for individuals with neurodegenerative diseases through CNM-Au8. The company is working towards regulatory approvals to bring this groundbreaking treatment to market. With its potential to improve mitochondrial function and enhance patient outcomes, CNM-Au8 represents a pioneering approach to treating neurodegenerative diseases.

To listen to the full podcast, visit https://ibn.fm/bTX5J.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• GivBux in October 2023 announced utility payments, international merchant payments and biometrics as new features in the latest release of its GivBux Super App
• That same month, the company expanded its ‘It Pays to Give’ policy to include advertising revenue sharing for Super App users
• Also in October 2023, GivBux named Umesh Singh as President and Michael Arnkvarn as Vice President of International Business Development
• In August 2023, the company launched its innovative super app after four years of development and testing

GivBux (OTC: GBUX) is a publicly traded super app and charitable giving platform. The company is creating a sharing economic community of brands and consumers in which consumers have an easier and more convenient way to shop and buy, merchants have a more efficient and profitable way to advertise, and charities receive built-in contributions from the community’s transactions.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to giving back. Additionally, the app is evolving to include numerous functionalities like social networking, e-commerce, banking, messaging, food delivery and transportation, following the super app model.

GivBux is forging a new path in charitable giving, with aspirations to build the largest community of givers in the United States, and eventually globally. The company believes it is uniquely positioned to make a major contribution to society by overlapping the worlds of commerce and philanthropy.

The GivBux Super App is currently available for free on the Google Play Store and the Apple App Store.

The company is headquartered in Newport Beach, California.

Products

The company, through wholly owned subsidiary GivBux Global Partners Inc., is engaged in the fintech mobile wallet sector, specifically as a point-of-sale payment system by means of a consumer mobile wallet. GivBux uses smartphone technology to bridge consumers and merchants together without the need for traditional plastic cards or paper cash.

The GivBux mobile app has been designed to store, send and receive funds; donate; and make real-time purchases at top retail brands, restaurants and other venues. The brands benefit, because they are empowered with a data-rich marketing tool to reach and retain consumers through their mobile phones.

With GivBux, recipients can use funds instantly by paying with their mobile phones at thousands of locations. GivBux rewards all users for using the app every time they make a purchase and every time their friends, friends of friends and stranger friends make purchases with the GivBux mobile wallet. These rewards can be redeemed for cash to pay at participating retail stores, restaurants, cinemas, entertainment venues and more.

Moreover, GivBux allows users to contribute to a charity or worthy cause of their choice. To encourage giving and recommendations, a trending ‘Top 10 List’ of all charities will be generated and displayed on the mobile wallet based on ongoing contributions by GivBux users.

Market Opportunity

A report from Future Market Insights, a New York-based market research organization, estimated the worldwide mobile wallet market at $9.5 billion in 2023. The report projects that in 2024 the industry is likely to reach a valuation of $11.9 billion, and, by 2034, the mobile wallet market is forecast to grow to a value of $138.5 billion, achieving a CAGR of 27.8% over the forecast period.

Key market growth drivers include payment convenience, transaction security and continuing technological innovation. The report points out that mobile wallet payments are widely accepted worldwide, fueled by a rise in digital transactions and a growing use of mobile phones for simple and effective payment options. Innovations like blockchain integration, contactless payments and artificial intelligence are improving functionality and user experience while staying ahead of rapidly evolving digital payment trends, according to the report.

Management Team

Umesh Singh is President and Director at GivBux. He is a Certified Professional Accountant (Canada) with more than 25 years of experience in accounting and finance. He began his career at PwC before joining Hayes Stuart Little & Company (now Grant Thornton), where he was Senior Accountant-Manager and later Partner. Prior to being named GivBux president, he was a member of the GivBux Advisory Board for more than three years.

Michael Arnkvarn is Vice President of International Business Development at GivBux. He has over 30 years of experience in management, sales and marketing. He managed several medium and large agribusiness and environmental businesses before founding Collagenna Skin Care Products, a natural health products and cosmetics company, in 2004. He has been CEO of multiple public small-cap companies and co-founder of a start-up cannabis company that eventually sold for more than $800 million.

For more information, visit the company’s website at www.GivBux.com.

NOTE TO INVESTORS: The latest news and updates relating to GBUX are available in the company’s newsroom at https://ibn.fm/GBUX

• DLMI, a multi-strategy operating company, is tapping into expanding digital securities and global blockchain industries by asserting itself as a trusted authority in the tokenization space
• In an interview with Proactive’s Stephen Gunnion, Brian J. Esposito, DLMI’s CEO, noted how tokenization is redefining investing by opening up global markets to real-world assets
• He reiterated his goal to build strong earnings, provide shareholder value with sustainable, healthy growth, and grow the DLMI brand

Diamond Lake Minerals (OTC: DLMI), a multi-strategy operating company specializing in the development and support of digital assets and SEC-registered tokens, is looking to capitalize on the growing digital securities market, with tokenization projected to reach over $16 trillion by 2030 (https://ibn.fm/jTaA8). It also plans to make the most of the growing global blockchain market, expected to hit $38.7 billion by 2025. The company is working to achieve this and more by doubling down on tokenization and asserting itself as a trusted authority in the tokenization space.

In an interview with Proactive’s Stephen Gunnion, Brian J. Esposito, DLMI’s CEO, reiterated how tokenization redefines investing by opening up global markets to real-world assets previously inaccessible to many investors. In addition, he noted the benefits of blockchain technology, comparing it with the challenges of traditional investment mechanisms, specifically in the real estate sectors.

“With technology and blockchain and everybody having a smart device, they have access to possibly buying into real-world assets and things that they never had the opportunity to buy into before,” noted Mr. Esposito (https://ibn.fm/oZfvO).

In the interview, Esposito noted how tokenization could democratize access to investment opportunities, ultimately creating liquidity and potentially enabling wealth generation for an even bigger fraction of the global population. He emphasized the importance of doing all this within the confines of the law, noting how DLMI does not look for grey areas to fulfill its mandate to customers and investors. Instead, Esposito welcomed the scrutiny that comes with regulation and regulatory bodies, noting that they are necessary for ensuring the safety and security of these new technological advances.

Esposito joined DLMI in August 2023, having had an illustrious and successful career thus far. Adria Management, LLC ranked him among the world’s top 10 CEOs for 2020, 2021, and 2022 in The World CEO Rankings Awards. While making his announcement upon joining DLMI, Esposito noted that his goal at the company would be to build strong earnings, provide shareholder value with sustainable healthy growth, and grow the brand into one of the highest-coveted securities in the market (https://ibn.fm/OqFMF).

In his interview with Gunnion, Esposito reiterated these goals, expressing his confidence in DLMI’s offering and its potential to assert the company as a market leader. DLMI has been described as “a company to watch” for good reason. Its value proposition is unique, it offers incredible value, and its market positioning is excellent. As the company continues leveraging tokenization and opening new opportunities for investors globally, DLMI affirms its commitment to shareholders while asserting itself as a frontrunner in its space.

A major step for the company was taken in February 2024, when DLMI announced a strategic investment in Avrio Worldwide to secure Avrio’s registered digital financial market infrastructure for the tokenization of digital assets across the DLMI network of companies. Avrio is essentially the financial services technology engine that will enable the DLMI network across a wide range of industries, unlocking access to liquidity and value for investors through a registered platform.

“AVRIO is the parent of several companies delivering licensed digital financial market infrastructure and services across public, private, and digital markets. Avrio’s ATS technology, Arkonis, is designed to be used by the operators of private markets that facilitate the issuance and secondary trading of securities and includes: a Quotation Bureau, a Transfer Agent, and a Qualified Matching Engine for LP investors. Avrio’s public market technology includes: an API farm for exchange management (‘EM’), order management (‘OM’), portfolio management (‘PM’), and client management (‘CM’) – and routes to global public markets. Avrio’s NFT technology provides exchange access and capabilities to trade digital asset securities and collectibles.” (https://ibn.fm/AYXzA).

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Bookings and revenue for the full year, as well as Q4 YOY, showed significant increases, with a number of operational and technical developments and market achievements
• Key additions to the leadership team include Lorenzo Martinelli as Chief Revenue Officer and Dr. Trevor Lanting as Chief Development Officer. Sec. Kirstjen Nielsen, former Secretary of Homeland Security, has joined the Board of Directors
• D-Wave’s current commercial product offerings include Advantage(TM), its fifth-generation quantum computer, the Leap(TM) quantum cloud service, the Launch(TM) quantum computing onboarding service, the Ocean(TM) suite of open-source programming tools, and the Quantum QuickStart(TM) quantum programming training

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in commercial quantum computing systems, software, and services, recently announced financial results for its fourth fiscal quarter and year ending December 31, 2023. D-Wave also hosted a conference call on Thursday, March 28, 2024, discussing the company’s financial results and business outlook. Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich participated in the call on behalf of the company.

“Our momentum is undeniable. From our commercial traction to substantive product advancements, from our ground-breaking scientific milestones to new strategic partnerships — we believe all these achievements are propelling us forward to solidify D-Wave’s position as the commercial quantum category builder and leader,” said Dr. Baratz (https://ibn.fm/X0t7d).

The company’s financial results and business outlook cover the fourth quarter and full year ending December 31, 2023, including key leadership appointments, company collaborations, and more. Details on the call can be found on the company’s investor page (https://ibn.fm/Jk9QW).

As covered in the earnings call, D-Wave has achieved significant business and technical developments. D-Wave has also made key additions to its leadership team, including appointing Lorenzo Martinelli as Chief Revenue Officer and Dr. Trevor Lanting as Chief Development Officer. Kirstjen Nielsen, former Secretary of Homeland Security, has joined D-Wave’s Board of Directors.

A recently announced strategic collaboration with Zapata AI aims to advance quantum-enabled machine learning, focusing initially on quantum generative AI models for material and molecule discovery. In addition, D-Wave has made progress with customer applications deployed in employee and driver scheduling, with more applications nearing production deployment. New and renewed customer engagements include agreements with Bridgestone Corp., Ford Otosan, and others, while partnerships with NEC Australia and Deloitte Canada aim to further accelerate the adoption of quantum computing solutions.

Financially, D-Wave has seen growth in bookings, revenue, and customer base, with consecutive quarters of year-over-year growth. The company ended fiscal year 2023 with $41.3 million in cash and raised $98.1 million in capital. Guidance for fiscal year 2024 anticipates a reduction in adjusted EBITDA loss compared to 2023 and expects first-quarter bookings to reach at least $4.3 million.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding fiscal year 2024 guidance. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including; the company’s ability to raise funds under the ELOC or meet the conditions necessary to draw on the third tranche of the PSP Loan; general economic conditions and other risks; the company’s ability to maintain and expand the company’s customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; like its hybrid solvers and software like “zero downtime deployment”; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of its securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Form 10-K for its fiscal year ended December 31, 2023 filed on March 29, 2024. Any such forward-looking statements represent management’s estimates as of the date of this press release. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• The global Asian food market value was estimated at $437.15 billion in 2022. The market is expected to reach approximately $805.08 billion by 2031, growing at a CAGR of 7.1% during the forecast period
• This recognition adds to I.Hart’s list of achievements, including multiple awards received by its chefs and culinary teams, such as the National Yushan Award for three consecutive years in categories like The Most Outstanding Enterprise, Outstanding Enterprise Leader, and The Best Product
• SUIC is the largest shareholder and major operating partner of Beneway Holdings Group, of which I.Hart Group is a subsidiary

SUIC Worldwide Holdings (OTC: SUIC), provides research and development, venture financing, and investment for private and public companies that develop products and services in the areas of Internet of Things, cloud computing, mobile payments, Big Data, blockchain, artificial intelligence and global franchising. The company recently announced that SUIC’s I.Hart Group has been acknowledged by the Taiwan government as exclusive catering group and awarded the Role Model status, demonstrating its excellence and innovation to global clients and partners (https://ibn.fm/YPXGp). This will advance I.Hart Group’s joint ventures that will bring together world-class business leaders and further its initiatives in the U.S. and in global markets – paving the way for fast growth of Beneway USA’s IPO.

According to Growth Market Reports, the global Asian food market value was estimated at $437.15 billion in 2022. The market is expected to reach approximately $805.08 billion by 2031, growing at a CAGR of 7.1% during the forecast period. The increased interest in home cooking and product innovation are driving the market’s rapid expansion in the Asian food market sector (https://ibn.fm/Gt4ZR).

The Taiwan government agency, O.C.A.C., has chosen I.Hart Group, Taiwan, as an exclusive role model. I.Hart Group will be showcasing its award-winning central kitchen, restaurant, and products during this special visit. This recognition adds to I.Hart’s impressive list of achievements, including multiple awards received by its chefs and culinary teams, such as the National Yushan Award for three consecutive years in categories like The Most Outstanding Enterprise, Outstanding Enterprise Leader, and The Best Product.

SUIC is the largest shareholder and major operating partner of Beneway Holdings Group, of which I.Hart Group is a subsidiary. Currently, I.Hart Group operates 150 franchised locations globally across various brands and products. The company is actively incorporating more successful brands into its Asian portfolio, such as Thai Food, Hainan Chicken, and Asia-style BBQ skewers. It aims to introduce 25 different brands into the US franchise market across all 50 states. Employing its successful multi-branding business model, I.Hart Group is collaborating with top franchise marketing and sales agencies in the US to expand and achieve its target of 750 franchises and self-owned restaurants before its IPO.

“Our vision and passion seek and create viable solutions using our new-generation technologies will empower our partner merchants, franchisees and suppliers and make a difference for our customers around the world, forming our global technology hub in the process,” said SUIC CEO Hank Wang. “This is how SUIC applies innovation power to bring about enduring value to our shareholders and to the society. We are committed to building on this legacy as SUIC and Beneway move forward together.”

SUIC works with Beneway in several business ventures, focusing on fintech, food industry supply chain integration, global chain and franchise expansion, and other supply chain integration. The company’s ventures seek to enhance and streamline existing processes and establish new and exciting business models that will create revolutionary products and services.

For more information, visit the company’s website at www.SinoUnitedCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC